Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 359,000 shares, a decrease of 15.6% from the March 15th total of 425,500 shares. Approximately 2.3% of the shares of the company are sold short. Based on an average daily volume of 43,300 shares, the short-interest ratio is presently 8.3 days.

Accelerate Diagnostics Price Performance

AXDX traded up $0.02 during trading on Monday, reaching $0.57. 2,053 shares of the stock were exchanged, compared to its average volume of 59,014. The company has a market capitalization of $14.27 million, a price-to-earnings ratio of -0.20 and a beta of 0.46. Accelerate Diagnostics has a 1 year low of $0.49 and a 1 year high of $2.09. The business’s 50 day moving average price is $0.93 and its two-hundred day moving average price is $1.30.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings data on Thursday, March 20th. The medical research company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.13. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $3.00 million. On average, analysts anticipate that Accelerate Diagnostics will post -2.3 EPS for the current year.

Institutional Investors Weigh In On Accelerate Diagnostics

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Accelerate Diagnostics by 6.9% during the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock worth $163,000 after acquiring an additional 8,777 shares during the last quarter. Renaissance Technologies LLC lifted its position in Accelerate Diagnostics by 160.6% during the fourth quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after buying an additional 65,984 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Accelerate Diagnostics in the 4th quarter worth about $27,000. Institutional investors and hedge funds own 17.14% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Accelerate Diagnostics in a research note on Friday. They set a “hold” rating for the company.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.